<DOC>
	<DOCNO>NCT02080884</DOCNO>
	<brief_summary>This study examine effectiveness MabThera therapy add standard chemotherapy regimen treatment previously untreated chronic lymphocytic leukemia ( CLL ) . Patients receive single prior MabThera plus chemotherapy treatment eligible . The overall response rate patient treat approximately 5 month ( per current label guideline ) analyse accord various factor ( i.e. , age , concurrent treatment , chromosomal abnormality ) .</brief_summary>
	<brief_title>An Observational Study Examining Effect Added MabThera Therapy Patients With Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosed firstline CLL receive 1 cycle MabThera chemotherapy age &gt; /= 18 year Pregnant breastfeed Receipt investigational drug within 30 day prior enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>